Medical

Study Shows Drug Halves Recurrence Rate In Patients With Early-Stage EGFR-Mutated Lung Cancer!

A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!

Apparatus

Ovarian Cancer Heavyweight Cutting-Edge ADC Drug Elahere Proven Safe And Effective

On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.

Medical

Innovative Therapy Zolbetuximab In Combination With Chemotherapy Significantly Improves Survival Of Gastric Cancer Patients!

New research confirms that the innovative treatment Zolbetuximab, in combination with chemotherapy, is highly effective in the treatment of gastric cancer, especially in advanced stages, and is expected to be a potential new treatment for patients with gastric cancer.

Hospital

MD Anderson Cancer Center, USA

MD Anderson Cancer Center, founded in 1941, is a world-renowned oncology hospital located in Houston, Texas, USA, and was one of the three early comprehensive cancer treatment centres designated by the National Cancer Initiative in 1971. It is one of the first three comprehensive cancer treatment centres designated by the National Cancer Initiative in 1971, and one of 39 comprehensive cancer treatment centres designated by the Medical Oncology Society, and is recognised as a good cancer hospital.

Apparatus

Heavyweight! First ADC Drug Approved For Hormone Receptor-Positive Breast Cancer!

The US FDA approved the ADC drug gosatumumab (Trodelvy) for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer. In the trial, the drug significantly extended the overall survival of patients and reduced the risk of death by 21%.

Medical

More Significant Survival Benefit For Non-Small Cell Lung Cancer Patients Under 55 Years Of Age, Also Using Immunotherapy!

Recent findings show that the use of cutting-edge immune checkpoint inhibitor therapy (referred to as immunotherapy in this article) has increased rapidly over the past decade in the population of patients with advanced non-small cell lung cancer (NSCLC), but the survival benefit is more pronounced in younger people than in older people, who have limited survival benefit with this therapy.

Hospital

Memorial Sloan Kettering Cancer Centre, USA

Memorial Sloan Kettering Cancer Center is the world's oldest and largest private cancer centre. for more than 130 years, the centre has been committed to excellence in patient care, innovative research and top-notch medical education programs

Disease

What Are The Common Symptoms Of Vocal Cord Cancer? How To Treat Vocal Cord Cancer?

Vocal cord cancer often leads to hoarseness, which is a common symptom of many diseases and can be easily overlooked by patients.

Apparatus

The New Generation Of Breast Cancer SERD Drug, Elastoxan, Shows Promise!

A new generation of oral selective estrogen receptor degrader, elastostat, has shown promise in clinical studies over standard second-line treatments such as fulvestrant for the treatment of patients with metastatic hormone receptor-positive breast cancer.

Medical

Three-drug Combination For HPV-positive Cancers Results In Significant Tumour Shrinkage In 88% Of Patients!

A three-drug combination regimen significantly prolongs survival in patients with HPV-positive cancers, new data from a clinical trial shows. For patients who had not been treated with immune checkpoint inhibitors, it resulted in significant tumour shrinkage in 88% of patients, and even in patients who failed immune checkpoint inhibitor treatment, 63% had significant tumour shrinkage.